{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:16:49Z","timestamp":1793049409570,"version":"4.5.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>5q-Spinal muscular atrophy (SMA) is a severely disabling inherited neuromuscular disease that progressively reduces the motor abilities of affected individuals. The approval of the antisense oligonucleotide nusinersen, which has been shown to improve motor function in adult SMA patients, changed the treatment landscape. However, little is known about its impact on patients' quality of life (QoL), and there is still a need for adequate patient-reported outcome measures. In this study, we used the short form of the Neuro-QoL (Quality of Life in Neurological Disorders) for upper\/lower extremity function to prospectively assess the health-related QoL of 17 adult SMA patients prior to initiation of nusinersen treatment and 2, 6, 10, and 14 months afterwards. At baseline, Neuro-QoL scores strongly correlated with motor function scores (Hammersmith Functional Motor Scale Expanded, HFMSE; Revised Upper Limb Module, RULM), but QoL did not increase significantly during the 14-month treatment period despite significant motor improvement as measured by HFMSE. Our results underline the need for novel, disease-specific assessments of QoL in SMA.<\/jats:p>","DOI":"10.3389\/fneur.2021.812063","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:18:03Z","timestamp":1642983483000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Assessment of Health-Related Quality of Life in Adult Spinal Muscular Atrophy Under Nusinersen Treatment\u2014A Pilot Study"],"prefix":"10.3389","volume":"12","author":[{"given":"Andreas","family":"Thimm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svenja","family":"Brakemeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Kizina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Munoz Rosales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Stolte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Totzeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelius","family":"Deuschl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kleinschnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Hagenacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1750-1172-6-71","article-title":"Spinal muscular atrophy","volume":"6","author":"D'Amico","year":"2011","journal-title":"Orphanet J Rare Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell."},{"key":"B3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fmolb.2016.00007","article-title":"Copy number variations in in the survival motor neuron genes: implications for spinal muscular atrophy and other neurodegenerative diseases","volume":"3","author":"Butchbach","year":"2016","journal-title":"Front Mol Biosci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ana.20473","article-title":"Natural history of denervation in SMA: relation to age, SMN2 copy number, and function","volume":"57","author":"Swoboda","year":"2005","journal-title":"Ann Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1007\/s00439-006-0156-7","article-title":"Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number","volume":"119","author":"Wirth","year":"2006","journal-title":"Hum Genet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","article-title":"Spinal muscular atrophy","volume":"371","author":"Lunn","year":"2008","journal-title":"Lancet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/ejhg.2011.134","article-title":"Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens","volume":"20","author":"Sugarman","year":"2012","journal-title":"Eur J Hum Genet."},{"key":"B8","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J Rare Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1053\/ejpn.1999.0181","article-title":"Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype","volume":"3","author":"Dubowitz","year":"1999","journal-title":"Eur J Paediatr Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1053\/ejpn.1999.0184","article-title":"Prenatal onset spinal muscular atrophy","volume":"3","author":"MacLeod","year":"1999","journal-title":"Eur J Paediatr Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41582-020-00413-4","article-title":"Spinal muscular atrophy - insights and challenges in the treatment era","volume":"16","author":"Mercuri","year":"2020","journal-title":"Nat Rev Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","article-title":"Onasemnogene abeparvovec: first global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s40265-020-01410-z","article-title":"Risdiplam: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs."},{"key":"B14","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","article-title":"Nusinersen: first global approval","volume":"77","author":"Hoy","year":"2017","journal-title":"Drugs."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1756286418776932","DOI":"10.1177\/1756286418776932","article-title":"Antisense oligonucleotides in neurological disorders","volume":"11","author":"Wurster","year":"2018","journal-title":"Ther Adv Neurol Disord."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","article-title":"Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study","volume":"2020","author":"Hagenacker","year":"2020","journal-title":"Lancet Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3233\/JND-200534","article-title":"Measuring outcomes in adults with spinal muscular atrophy - challenges and future directions - meeting report","volume":"7","author":"Sansone","year":"2020","journal-title":"J Neuromuscul Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/jpm10030075","article-title":"The identification of novel biomarkers is required to improve adult SMA patient stratification, diagnosis and treatment","volume":"10","author":"Smeriglio","year":"2020","journal-title":"J Pers Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1212\/WNL.0b013e318258f744","article-title":"Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology","volume":"78","author":"Cella","year":"2012","journal-title":"Neurology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13023-020-1339-3","article-title":"Health, wellbeing and lived experience of adults with SMA: a scoping systematic review","volume":"15","author":"Wan","year":"2020","journal-title":"Orphanet J Rare Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ejpn.2019.03.004","article-title":"Quality of life of patients with spinal muscular atrophy: a systematic review","volume":"23","author":"Landfeldt","year":"2019","journal-title":"Eur J Paediatr Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1212\/WNL.0b013e318271f7e4","article-title":"Prospective cohort study of spinal muscular atrophy types 2 and 3","volume":"79","author":"Kaufmann","year":"2012","journal-title":"Neurology."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1007\/s00415-008-0929-0","article-title":"A natural history study of late onset spinal muscular atrophy types 3b and 4","volume":"255","author":"Piepers","year":"2008","journal-title":"J Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12955-018-1062-0","article-title":"A review of quality of life themes in duchenne muscular dystrophy for patients and carers","volume":"16","author":"Uttley","year":"2018","journal-title":"Health Qual Life Outcomes."},{"key":"B27","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1055\/s-0033-1347935","article-title":"Self-reported quality of life and depressive symptoms in children, adolescents, and adults with duchenne muscular dystrophy: a cross-sectional survey study","volume":"44","author":"Elsenbruch","year":"2013","journal-title":"Neuropaediatrics."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1542\/peds.2012-0858","article-title":"Health-related quality of life in children and adolescents with duchenne muscular dystrophy","volume":"130","author":"Uzark","year":"2012","journal-title":"Pediatrics."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"McDonald","year":"2017","journal-title":"Lancet."},{"key":"B30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12883-017-0790-9","article-title":"Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy","volume":"17","author":"Pera","year":"2017","journal-title":"BMC Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2021.626787","article-title":"Quality of life in SMA patients under treatment with nusinersen","volume":"12","author":"Mix","year":"2021","journal-title":"Front Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"729","DOI":"10.2147\/PPA.S305849","article-title":"Proxy-reported quality of life and access to nusinersen among patients with spinal muscular atrophy in Saudi Arabia","volume":"15","author":"AlRuthia","year":"2021","journal-title":"Patient Prefer Adherence."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1756286421998902","article-title":"Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy","volume":"14","author":"Osmanovic","year":"2021","journal-title":"Ther Adv Neurol Disord."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1111\/ene.14902","article-title":"Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersen","volume":"28","author":"Meyer","year":"2021","journal-title":"Eur J Neurol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"11069","DOI":"10.1038\/s41598-020-68051-w","article-title":"Fatigue in adults with spinal muscular atrophy under treatment with nusinersen","volume":"10","author":"Kizina","year":"2020","journal-title":"Sci Rep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.nmd.2021.02.006","article-title":"The spinal muscular atrophy health index: a novel outcome for measuring how a patient feels and functions","volume":"63","author":"Zizzi","year":"2021","journal-title":"Muscle Nerve."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1007\/s00415-020-09847-8","article-title":"Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy","volume":"267","author":"Osmanovic","year":"2020","journal-title":"J Neurol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"525560","DOI":"10.3389\/fpsyg.2020.525560","article-title":"Disease acceptance and eudemonic well-being among adults with physical disabilities: the mediator effect of meaning in life","volume":"11","author":"Szczesniak","year":"2020","journal-title":"Front Psychol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.812063\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:18:06Z","timestamp":1642983486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.812063\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,24]]},"references-count":38,"alternative-id":["10.3389\/fneur.2021.812063"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.812063","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,24]]},"article-number":"812063"}}